News & Events zu Brainsway Ltd (BWAY)BWAYBrainsway Ltd

BrainsWay Expands Medical Policy Coverage to 70 Million in the U.S.

BrainsWay announced further expansion in the number of medical policies across the U.S. providing coverage for its Swift Accelerated Deep TMS protocol. With this update, there are now over 70M covered lives in the U.S. with access to policies covering Swift. The announcement comes amid continued momentum in favorable policy changes for Deep TMS generally, including for the treatment major depressive disorder and obsessive-compulsive disorder patients.

BrainsWay Publishes Results of Deep Brain Stimulation Study

BrainsWay announced the publication of results from a pilot study evaluating the company's proprietary Deep Transcranial Magnetic Stimulation technology in patients with co-occurring Major Depressive Disorder and early-stage Alzheimer's disease. The results were published in the peer-reviewed Journal of Geriatric Psychiatry and Neurology. The study, conducted by researchers from the Delray Center for Brain Science and the Department of Psychology at Florida Atlantic University, included 12 patients who received 36 Deep TMS sessions using BrainsWay's H1 and H7 Coils. The treatment protocol involved stimulation of the left dorsolateral prefrontal cortex with the H1 Coil, followed by stimulation of the temporal regions with the H7 Coil. The study reported an 83.3% response rate and a 50% remission rate in depressive symptoms following Deep TMS treatment. In addition to the clinical outcomes, researchers observed changes in brain activity using quantitative electroencephalography, a technique that compares electrophysiological brain patterns, before and after treatment. This included a reduction of power in the delta frequency band in the right temporal lobe after treatment, which could suggest reduced cortical slowing - a common biological phenomenon associated with Alzeimer's disease. In addition, an increase in alpha coherence - a measure of synchronization and functional connectivity between different brain regions - was observed between several frontal and temporal sites, suggesting an improvement upon the brain dysconnectivity often implicated in Alzheimer's disease.

BrainsWay Raises FY26 Financial Guidance to $13M-$14M

Consensus $67.65M. Narrows FY26 adjusted EBITDA view to $13M-$14M from $12M-$14M. "This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a record $17.1 million, Adjusted EBITDA more than doubled to $3.5 million, and we generated more than $6.0 million of operating cash flow. Record system shipments and RPO of $80.4 million further strengthen our visibility into continued growth," said Hadar Levy, Chief Executive Officer of BrainsWay. "We are seeing strong momentum across the business, which is fueled by expanding reimbursement coverage and increasing utilization throughout our installed base. As a result, we are raising our full-year financial guidance for 2026."